• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

    11/4/24 7:39:24 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email
    SC 13G/A 1 zk2432211.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934

    Akoya Biosciences, Inc.
    (Name of Issuer)
     
    Common Stock, Par Value $0.00001 per Share
    (Title of Class of Securities)
     
     00974H104

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☒ Rule 13d-1(c)
     
    ☐ Rule 13d-1(d)
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
     


    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund II, L.P.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    4,672,670
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,672,670
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,672,670
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    9.44%(1)
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 2 of 17 Pages


    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund II G.P., L.P.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    4,672,670
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,672,670
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,672,670
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    9.44%(1)
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.
     
    Page 3 of 17 Pages



    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    aMoon Growth II General Partner Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    4,672,670
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,672,670
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,672,670
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    9.44%(1)
    12.
    Type of Reporting Person (See Instructions)
     
    CO
     
    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 4 of 17 Pages


    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    aMoon Edge Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    205,789
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    205,789
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    205,789
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    0.42% (1) 
    12.
    Type of Reporting Person (See Instructions)
     
    PN

    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 5 of 17 Pages

     
    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    aMoon Edge GP Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    205,789
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    205,789
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    205,789
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    0.42% (1) 
    12.
    Type of Reporting Person (See Instructions)
     
    CO

    (1)
     Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 6 of 17 Pages


    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    Hilliyon Holdings Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    205,789
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    205,789
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    205,789
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    0.42% (1) 
    12.
    Type of Reporting Person (See Instructions)
     
    CO

    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 7 of 17 Pages


    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    Berko Capital Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    205,789
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    205,789
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    205,789
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    0.42% (1) 
    12.
    Type of Reporting Person (See Instructions)
     
    CO

    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 8 of 17 Pages


    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    Dr. Yair C. Schindel
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    4,878,459
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,878,459
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,878,459
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    9.86% (1)
    12.
    Type of Reporting Person (See Instructions)
     
    IN

    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 9 of 17 Pages

     
    CUSIP No.
    00974H104
    1.
    Names of Reporting Persons
     
    Dr. Tomer Berkovitz
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☑
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power
     
    205,789
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    205,789
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    205,789
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    0.42% (1) 
    12.
    Type of Reporting Person (See Instructions)
     
    IN

    (1)
    Based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    Page 10 of 17 Pages


    Item 1(a)
    Name of Issuer
     

    Akoya Biosciences, Inc. (the “Issuer”).
     
    Item 1(b)
    Address of Issuer’s Principal Executive Offices
     

    100 Campus Drive, 6th Floor, Marlborough, MA 01752.
     
    Item 2(a)-(b)
    Name of Person Filing; Address of Principal Business Office or, if none, Residence
     

    1.
    aMoon Growth Fund II, L.P. (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    2.
    aMoon Growth Fund II G.P., L.P. (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    3.
    aMoon Growth II General Partner Ltd., (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    4.
    aMoon Edge Limited Partnership (“aMoon Edge”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    5.
    aMoon Edge GP Ltd., (“aMoon Edge Ltd.”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    6.
    Hilliyon Holdings Ltd., (“Hilliyon”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    7.
    Berko Capital Ltd., an Israeli company (“Berko Capital”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    8.
    Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    9.
    Dr. Tomer Berkovitz (“Berkovitz”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”.

    Item 2(c)
    Citizenship
     

    aMoon is a Cayman Islands exempted limited partnership; aMoon G.P. is a Cayman Islands exempted limited partnership; aMoon Ltd. is an Israeli company; aMoon Edge is a Cayman Islands exempted limited partnership; aMoon Edge Ltd. is a Cayman Islands company; Hilliyon is an Israeli company; Berko Capital is an Israeli company; Schindel is an Israeli citizen and Berkovitz is an Israeli citizen.
     
    Page 11 of 17 Pages

    Item 2(d)
    Title of Class of Securities
     

    Common Stock, par value $0.00001 per share

    Item 2(e)
    CUSIP Number
     

    00974H104
     
    Item 3
    If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     

    Not applicable.
     
    Item 4
    Ownership

    All share percentage calculation below are based on 49,499,487 shares of Common Stock issued and outstanding at July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on August 6, 2024.

    aMoon Growth Fund II, L.P.


    (a)
    Amount beneficially owned:  4,672,670 shares of Common Stock.


    (b)
    Percent of Class: 9.44%


    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,672,670 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,672,670 shares of Common Stock

    aMoon Growth Fund II G.P., L.P.


    (a)
    Amount beneficially owned:  4,672,670 shares of Common Stock.


    (b)
    Percent of Class: 9.44%


    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,672,670 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,672,670 shares of Common Stock.

    aMoon Growth II General Partner Ltd.


    (a)
    Amount beneficially owned:  4,672,670 shares of Common Stock.


    (b)
    Percent of Class: 9.44%

    Page 12 of 17 Pages

     

    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,672,670 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,672,670 shares of Common Stock.

    aMoon Edge Limited Partnership


    (a)
    Amount beneficially owned:  205,789 shares of Common Stock.


    (b)
    Percent of Class: 0.42%


    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 205,789 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

    aMoon Edge GP Ltd.


    (a)
    Amount beneficially owned:  205,789 shares of Common Stock.


    (b)
    Percent of Class: 0.42%


    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 205,789 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

    Hilliyon Holdings Ltd.


    (a)
    Amount beneficially owned:  205,789 shares of Common Stock.


    (b)
    Percent of Class: 0.42%


    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 205,789 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

    Berko Capital Ltd.


    (a)
    Amount beneficially owned:  205,789 shares of Common Stock.


    (b)
    Percent of Class: 0.42%


    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 205,789 shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

    Page 13 of 17 Pages


    Dr. Yair C. Schindel


    (a)
    Amount beneficially owned: 4,878,459 shares of Common Stock.  (i) Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon; (ii) aMoon Edge Ltd. is the sole general partner of aMoon Edge pursuant to the terms of the limited partnership agreement of aMoon Edge.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd. and Schindel is the sole shareholder of Hilliyon. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Schindel disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon, aMoon G.P. aMoon Ltd., aMoon Edge, aMoon Edge Ltd., and Hilliyon, except to the extent of his pecuniary interest therein, if any.


    (b)
    Percent of Class: 9.86%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,878,459  shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,878,459 shares of Common Stock.

    Dr. Tomer Berkovitz


    (a)
    Amount beneficially owned: 205,789 shares of Common Stock.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd., and Berkovitz is the sole shareholder of Berko Capital. By virtue of such relationships, Berkovitz may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Berkovitz disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon Edge, aMoon Edge Ltd. and Berko Capital, except to the extent of his pecuniary interest therein, if any.


    (b)
    Percent of Class: 0.42%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 205,789  shares of Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock

    Item 5
    Ownership of Five Percent or Less of a Class
     
    Not applicable.
     
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person
     
    Not applicable.
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     
    Not applicable.
     
    Page 14 of 17 Pages

     
    Item 8
    Identification and Classification of Members of the Group
     

    Incorporated by reference to Items 2 and 4 of this Schedule 13G.
     
    Item 9
    Notice of Dissolution of Group
     

    Not applicable.

    Item 10
    Certification
     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Page 15 of 17 Pages

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: November 4, 2024
     
    AMOON GROWTH FUND II L.P.
    BY: AMOON GROWTH FUND II G.P., L.P., ITS GENERAL PARTNER
    BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER

    By:
    /s/ Dr. Yair C. Schindel
     
    Name:
    Title:
    Dr. Yair C. Schindel
    Director
     
    AMOON GROWTH FUND II G.P., L.P.,
    BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER

    By:
    /s/ Dr. Yair C. Schindel
     
    Name:
    Title:
    Dr. Yair C. Schindel
    Director

    AMOON GROWTH II GENERAL PARTNER LTD.
     
    By:
    /s/ Dr. Yair C. Schindel
     
    Name:
    Title:
    Dr. Yair C. Schindel
    Director
     
    AMOON EDGE LIMITED PARTNERSHIP
    BY:  AMOON EDGE GP LTD., ITS GENERAL PARTNER
     
    By:
    /s/ Dr. Yair C. Schindel
     
    Name:
    Title:
    Dr. Yair C. Schindel
    Director
     
    Page 16 of 17 Pages


    AMOON EDGE GP LTD.
     
    By:
    /s/ Dr. Yair C. Schindel
     
    Name:
    Title:
    Dr. Yair C. Schindel
    Director

    HILLIYON HOLDINGS LTD.
     
    By:
    /s/ Dr. Yair C. Schindel
     
    Name:
    Title:
    Dr. Yair C. Schindel
    Director

    BERKO CAPITAL LTD.
     
    By:
    /s/ Dr. Tomer Berkovitz
     
    Name:
    Title:
    Dr. Tomer Berkovitz
    Director

    DR. YAIR C. SCHINDEL

    /s/ Dr. Yair C. Schindel
     

    DR. TOMER BERKOVITZ
     
    /s/ Dr. Tomer Berkovitz
     

    Page 17 of 17 Pages

    Get the next $AKYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKYA

    DatePrice TargetRatingAnalyst
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    8/6/2024Buy → Neutral
    BTIG Research
    8/6/2024Overweight → Neutral
    JP Morgan
    6/21/2024$7.50Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$14.00Buy
    UBS
    More analyst ratings

    $AKYA
    SEC Filings

    See more
    • SEC Form 425 filed by Akoya BioSciences Inc.

      425 - Akoya Biosciences, Inc. (0001711933) (Subject)

      5/12/25 4:11:23 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akoya Biosciences, Inc. (0001711933) (Filer)

      5/12/25 4:10:15 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Akoya BioSciences Inc.

      425 - Akoya Biosciences, Inc. (0001711933) (Subject)

      5/12/25 4:08:50 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      11/4/24 7:39:24 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Akoya BioSciences Inc.

      SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

      8/28/24 10:45:17 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      2/14/24 4:09:03 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akoya Biosciences downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

      11/15/24 8:33:16 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by Morgan Stanley

      Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

      8/6/24 12:17:30 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by BTIG Research

      BTIG Research downgraded Akoya Biosciences from Buy to Neutral

      8/6/24 6:28:51 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Ek John Frederick covered exercise/tax liability with 16,432 shares, decreasing direct ownership by 6% to 248,202 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      4/3/25 5:14:37 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Mckelligon Brian covered exercise/tax liability with 7,550 shares, decreasing direct ownership by 2% to 420,126 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:34:07 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Business Officer Ramachandran Niro Ph.D covered exercise/tax liability with 2,310 shares, decreasing direct ownership by 0.80% to 287,210 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:32:42 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Financials

    Live finance-specific insights

    See more

    $AKYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

      MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

      3/17/25 4:00:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

      Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

      1/10/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

      It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

      4/30/25 8:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix and Akoya Biosciences Announce Amended Merger Agreement

      Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ:AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9 million fewer

      4/29/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Akoya Biosciences Announces Leadership Transition

      Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

      3/20/23 4:00:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

      MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

      2/28/23 8:00:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

      MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

      4/19/22 8:05:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials